Kiniksa Pharmaceuticals International PLC - Class A (KNSA) closed at $95.05 on November 18, 2026, down 0.1% from the previous close, on volume of 315,825 shares (30-day average 782,454).
Data as of November 18, 2026.
Kiniksa Earnings Call Signals Strong ARCALYST Momentum
TipRanks (Sat, 14-Nov 9:21 PM ET)
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
Globe Newswire (Wed, 11-Nov 4:01 PM ET)
Kiniksa (KNSA) lifts 2026 ARCALYST revenue outlook to $1.045–$1.050B as Q3 sales reach $286.00M
Market Chameleon (Tue, 27-Oct 7:35 AM ET)
Kiniksa (KNSA) lifts 2026 ARCALYST outlook to $1.05B as Q3 revenue hits $286M
Market Chameleon (Tue, 27-Oct 3:41 AM ET)
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
Globe Newswire (Tue, 27-Oct 7:30 AM ET)
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Globe Newswire (Fri, 4-Sep 4:01 PM ET)
Impressive ARCALYST Growth and Strong Financials Signal Kiniksa's Momentum in 2026
Market Chameleon (Tue, 28-Jul 7:06 AM ET)
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.
As of November 19, 2026, KNSA stock price climbed to $95.21 with 163,378 million shares trading.
KNSA has a beta of 0.07, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.00 to the broad based SPY ETF.
KNSA has a market cap of $7.48 billion. This is considered a Mid Cap stock.
Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $286 million in Revenue and $.56 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $.23.
In the last 3 years, KNSA traded as high as $99.31 and as low as $15.51.
The top ETF exchange traded funds that KNSA belongs to (by Net Assets): IWM, VTI, VB, VBK, IWO.
KNSA has outperformed the market in the last year with a price return of +130.6% while the SPY ETF gained +10.9%. KNSA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.8% and -0.9%, respectively, while the SPY returned -5.4% and -5.5%, respectively.
KNSA support price is $91.94 and resistance is $98.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.